MCID: HYP457
MIFTS: 44

Hypertrophic Scars

Categories: Skin diseases

Aliases & Classifications for Hypertrophic Scars

MalaCards integrated aliases for Hypertrophic Scars:

Name: Hypertrophic Scars 41
Scars Hypertrophic 55

Classifications:



External Ids:

ICD10 33 L91.0

Summaries for Hypertrophic Scars

MalaCards based summary : Hypertrophic Scars, also known as scars hypertrophic, is related to scleroderma, familial progressive and localized scleroderma. An important gene associated with Hypertrophic Scars is TGFB1 (Transforming Growth Factor Beta 1), and among its related pathways/superpathways are GPCR Pathway and TGF-Beta Pathway. The drugs Clobetasol and Heparin have been mentioned in the context of this disorder. Affiliated tissues include skin, breast and endothelial, and related phenotypes are growth/size/body region and cardiovascular system

Wikipedia : 75 A hypertrophic scar is a cutaneous condition characterized by deposits of excessive amounts of collagen... more...

Related Diseases for Hypertrophic Scars

Diseases related to Hypertrophic Scars via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 145)
# Related Disease Score Top Affiliating Genes
1 scleroderma, familial progressive 30.7 CD36 BMP6
2 localized scleroderma 30.2 TGFB1 SMAD3
3 renal fibrosis 28.4 TGFB1 SMAD3 SMAD2 CD36 BMP6
4 epidermolysis bullosa dystrophica, pretibial 11.3
5 desmoid tumor 11.2
6 keloid disorder 11.0
7 peyronie disease 10.4 TGFB3 TGFB1
8 autosomal recessive cutis laxa type i 10.4 TGFB1 SMAD2
9 penile disease 10.4 TGFB1 SMAD2
10 keloid formation 10.4
11 osteochondrosis 10.4 TGFB1 CD36
12 cholecystolithiasis 10.4 TGFB1 BMP6
13 spastic paraplegia 3, autosomal dominant 10.3 TGFB1 SMAD2
14 melorheostosis 10.3 SMAD2 BMP6
15 neurofibromatosis, type ii 10.3
16 dowling-degos disease 1 10.3
17 skin disease 10.3
18 osteofibrous dysplasia 10.3 TGFB1 CD36
19 dupuytren contracture 10.3 TGFB1 BMP6
20 ocular cicatricial pemphigoid 10.3 TGFB1 CD36
21 odontogenic myxoma 10.3 MMP2 CD36
22 overgrowth syndrome 10.2
23 folliculitis 10.2
24 exanthem 10.2
25 cytokine deficiency 10.2
26 newcastle disease 10.1 MMP2 CD36
27 loeys-dietz syndrome 4 10.1 TGFB3 SMAD3
28 juvenile nasopharyngeal angiofibroma 10.1 TGFB3 BMP6
29 fibrosis of extraocular muscles, congenital, 1 10.1
30 enhanced s-cone syndrome 10.1
31 herpes zoster 10.1
32 proteasome-associated autoinflammatory syndrome 1 10.0
33 telangiectasis 10.0
34 basal cell carcinoma 10.0
35 stevens-johnson syndrome/toxic epidermal necrolysis 10.0
36 fibromatosis, gingival, 1 10.0 TGFB1 MMP2 CD36
37 tuberculoid leprosy 10.0 TGFB3 TGFB1 BMP6
38 hypertensive heart disease 10.0 MMP2 CD36
39 sarcoidosis 1 10.0
40 galactorrhea 10.0
41 retinal dystrophy, iris coloboma, and comedogenic acne syndrome 10.0
42 hyperprolactinemia 10.0
43 sarcoma 10.0
44 skin atrophy 10.0
45 purpura 10.0
46 systemic scleroderma 10.0
47 spindle cell sarcoma 10.0
48 cutaneous fibrous histiocytoma 10.0
49 cleft lip 10.0
50 neurofibroma 10.0

Graphical network of the top 20 diseases related to Hypertrophic Scars:



Diseases related to Hypertrophic Scars

Symptoms & Phenotypes for Hypertrophic Scars

MGI Mouse Phenotypes related to Hypertrophic Scars:

46 (show all 12)
# Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 10.11 BMP6 CD36 KRT16 MMP2 SMAD2 SMAD3
2 cardiovascular system MP:0005385 10.05 CD36 MMP2 SMAD2 SMAD3 TGFB1 TGFB3
3 homeostasis/metabolism MP:0005376 10.01 CD36 KRT16 MMP2 SMAD2 SMAD3 TGFB1
4 hematopoietic system MP:0005397 9.98 CD36 MMP2 SMAD2 SMAD3 TGFB1 TGFB3
5 craniofacial MP:0005382 9.97 KRT16 MMP2 SMAD2 SMAD3 TGFB1 TGFB3
6 digestive/alimentary MP:0005381 9.95 CD36 KRT16 SMAD2 SMAD3 TGFB1 TGFB3
7 mortality/aging MP:0010768 9.92 CD36 KRT16 MMP2 SMAD2 SMAD3 TGFB1
8 immune system MP:0005387 9.91 CD36 MMP2 SMAD2 SMAD3 TGFB1 TGFB3
9 neoplasm MP:0002006 9.65 MMP2 SMAD2 SMAD3 TGFB1 TIMP1
10 skeleton MP:0005390 9.56 BMP6 CD36 MMP2 SMAD2 SMAD3 TGFB1
11 respiratory system MP:0005388 9.55 MMP2 SMAD2 TGFB1 TGFB3 TIMP1
12 vision/eye MP:0005391 9.1 CD36 MMP2 SMAD2 SMAD3 TGFB1 TGFB3

Drugs & Therapeutics for Hypertrophic Scars

Drugs for Hypertrophic Scars (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 88)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Clobetasol Approved, Experimental, Investigational Phase 4 25122-46-7, 25122-41-2 32798 5311051
2
Heparin Approved, Investigational Phase 4 9005-49-6 46507594 772
3
Allantoin Approved Phase 4 97-59-6 204
4
Ethanol Approved Phase 4 64-17-5 702
5
Hydrocortisone acetate Approved, Vet_approved Phase 4 50-03-3
6
Tocopherol Approved, Investigational Phase 4 1406-66-2, 54-28-4 14986
7
Hydrocortisone Approved, Vet_approved Phase 4 50-23-7 5754
8
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
9
Triamcinolone Approved, Vet_approved Phase 4 124-94-7 31307
10
leucovorin Approved Phase 4 58-05-9 143 6006
11
Dapsone Approved, Investigational Phase 4 80-08-0 2955
12
Vitamin E Approved, Nutraceutical, Vet_approved Phase 4 59-02-9 14985
13
Folic acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
14 Tocotrienol Investigational Phase 4 6829-55-6
15 Dermatologic Agents Phase 4
16 Emollients Phase 4
17 Fibrinolytic Agents Phase 4
18 Anticoagulants Phase 4
19 calcium heparin Phase 4
20 Micronutrients Phase 4
21 Nutrients Phase 4
22 Trace Elements Phase 4
23 Antioxidants Phase 4
24 Hydrocortisone-17-butyrate Phase 4
25 Vitamins Phase 4
26 Tocotrienols Phase 4
27 Tocopherols Phase 4
28 Anti-Infective Agents, Local Phase 4
29 Hydrocortisone 17-butyrate 21-propionate Phase 4
30 Hydrocortisone hemisuccinate Phase 4
31 Anti-Inflammatory Agents Phase 4
32 glucocorticoids Phase 4
33 Hormones Phase 4
34 Hormone Antagonists Phase 4
35 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4
36 Neuromuscular Agents Phase 4
37 Peripheral Nervous System Agents Phase 4
38 Anesthetics, Local Phase 4
39 triamcinolone acetonide Phase 4
40 Sodium Channel Blockers Phase 4
41 Triamcinolone diacetate Phase 4
42 Triamcinolone hexacetonide Phase 4
43 Diuretics, Potassium Sparing Phase 4
44 Central Nervous System Depressants Phase 4
45 Anti-Arrhythmia Agents Phase 4
46 Immunosuppressive Agents Phase 4
47 Anesthetics Phase 4
48 Anti-Bacterial Agents Phase 4
49 Anti-Infective Agents Phase 4
50 Antiparasitic Agents Phase 4

Interventional clinical trials:

(show top 50) (show all 56)
# Name Status NCT ID Phase Drugs
1 Use of Silicone Gel to Improve Retroauricular Scar in Microtia Patients Unknown status NCT02518035 Phase 4 Silicone Gel
2 Treatment of Hypertrophic Scars Using Fractional Laser and Fractional Laser-assisted Topical Corticosteroid Delivery Completed NCT02487212 Phase 4 0.05% Clobetasol propionate;Petrolatum gel
3 Effect of Transparent, Self-drying Silicone Gel on the Treatment of Hypertrophic Abdominal Scars Completed NCT01078428 Phase 4
4 1540nm Non Ablative Fractional Laser Treatment of Scars : a Prospective Single Blinded Within Patient Controlled Randomized Trial. Completed NCT01056211 Phase 4
5 Effect of Silicone Gel Versus Contractubex Phonophoresis for Post-burn Hypertrophic Scars: A Single Blind Randomized Controlled Trial Completed NCT03777891 Phase 4
6 Assessment of Efficacy, Safety and Tolerability of Stratamark® (Innovative Self-drying Silicone Gel) in the Treatment and Prevention of Striae Distensae Completed NCT03377231 Phase 4
7 A Prospective, Randomized, Investigator-blinded, Placebo-controlled, Comparative Study Evaluating the Tolerability and Efficacy of Two Topical Therapies for the Treatment of Keloids and Hypertrophic Scars Completed NCT00754247 Phase 4 0.5% hydrocortisone, silicone, vitamin E lotion;Onion extract gel;Cetearyl alcohol lotion
8 Intralesional Injection of Steroids and/or Botulinum Toxin Type A in Hypertrophic Scars and Keloids for Pain Improvement Recruiting NCT03982862 Phase 4 Triamcinolone;Lidocaine;Botulinum toxin A
9 An Open-label Study to Investigate the Efficacy and Tolerability of Aczone Gel, 7.5% in the Treatment of Acne Vulgaris in Men and Women With Skin of Color Recruiting NCT03681470 Phase 4 Aczone Gel
10 Silicone Gel Versus Onion Extract Gel as Prevention for Postsurgical Scars: a Randomized Controlled Trial Unknown status NCT01861119 Phase 3 Silicone gel Kelo-cort™;;Onion extract gel Contractubex™
11 Topical Treatment With Glucocorticoids to Prevent Hypertrophic Scars and Keloid Due to Central Venous Access in Children Unknown status NCT01113125 Phase 3 Betamethason-17-valerate and fusidic acid;Fusidic Acid
12 Efficacy of CICATRIX (Asian Gotu Kola or Pennywort) in the Treatment of Hypertrophic Scars and Keloids Scars. Completed NCT00993005 Phase 3
13 Clinical Evaluation of Silicone Gel in the Treatment of Cleft Lip Scars Completed NCT03314090 Phase 3 Silicone Gels
14 Role of Topical Putrescine (Fibrostat) in 10%Urea (TFU) for Prevention of Hypertrophic Scars in Mammoplasty Patients Completed NCT03376620 Phase 3 1,4-Diaminobutane;10% Urea cream
15 An Open-label, Non Randomized, Single-Center Registry Study to Assess the Safety and Effects of Autologous Platelets Concentrate and Autologous Thrombin for the Treatment of Deep Burns Trauma Completed NCT01383187 Phase 2, Phase 3
16 Botulinum Toxin to Improve Results in Epicanthoplasty Recruiting NCT03294382 Phase 3 Botulinum toxin type A;Placebo
17 The Efficacy and Molecular Mechanism of Botulinum Toxin in the Reduction of Breast Reduction Mammoplasty Scar Formation: A Prospective, Controlled, Randomized, Double-blinded Study Not yet recruiting NCT03887377 Phase 2, Phase 3 Botulinum Toxins;Normal saline
18 Influencing Wound Healing Through the Application of Hyaluronic Acid With Perfluorodecalin and Physalis Angulata Extract After Split Skin Removal From the Thigh - A Study in "Split Wound Design" Withdrawn NCT03668665 Phase 3 Ready Medical Post Treatment
19 Botulinum Toxin A in the Healing of Surgical Wounds of the Neck: a Randomized, Prospective, Placebo-controlled Trial Unknown status NCT01177358 Phase 2 Botulinum Toxin Type A;Normal Saline
20 Phase 2 Of Injectable Collagenase (Xiaflex) For Burns' Associated Contracture Unknown status NCT01237964 Phase 2 Xiaflex (FDA approved collagenase)
21 A Phase 2, Open-label Study to Provide Revision of Scars Resulting From Surgery in Prior Studies of EXC 001 (Currently Called PF-06473871) Completed NCT01494922 Phase 2 EXC 001 (currently called PF-06473871)
22 A Multi-Center, Prospective, Randomized, Double-Blind, Within-Subject Controlled, Phase 2a Study to Evaluate the Effectiveness and Safety of RXI 109 on the Outcome of Scar Revision Surgery on Transverse Hypertrophic Scars on the Lower Abdomen Resulting From Previous Surgeries in Healthy Adults Completed NCT02030275 Phase 2 RXI-109;Placebo
23 Treatment of Hypertrophic Scars With Intradermal Botox Recruiting NCT03631368 Phase 2 Botox
24 An Open-Label, Multi-Center, Prospective, Within-Subject Controlled, Phase 2a Study to Evaluate the Effectiveness and Safety of RXI 109 on the Outcome of Scar Revision Surgery for Hypertrophic Scars in Healthy Adults Active, not recruiting NCT02246465 Phase 2 RXI-109
25 A Long-term Efficacy Assessment Following Initial Scar Revision Surgery And Phase 2 Open-label Study To Evaluate Safety Of Re-treatment With Pf-06473871 Terminated NCT02205476 Phase 2 PF-06473871;PF-06473871
26 Phase II Trial of Sorafenib in Patients With Extensive Keloids Terminated NCT01425216 Phase 2 Sorafenib
27 Within-subject Randomized Clinical Trial Comparing Dual-mode ER:YAG Laser in Patients With Long Keloid/Hypertrophic Scars Withdrawn NCT02546076 Phase 2
28 Gene Expression During Surgical Scar Remodeling by Fractional Photothermolysis Unknown status NCT01858038 Phase 1
29 A Phase 1, Single Center, Placebo-controlled, Interventional Study to Evaluate the Safety, Tolerability, and Pharmacokinetic Profiles in Healthy Subjects Compared to Placebo Completed NCT03569267 Phase 1 OLX10010;Placebo
30 The Safety of Topically Delivered FS2 in Humans. Phase 1 Clinical Trial Completed NCT02340325 Phase 1 Acute Application of kynurenic acid cream;Chronic application of kynurenic acid cream
31 Double Blind, Single-Center, Randomized, Within Subject Placebo, Phase I Study Evaluating the Effects of Novel Topical Gel in Prevention of Hypertrophic Scar Formation Recruiting NCT03403621 Phase 1 Pentamidine Isethionate;Silicone Gels
32 A Pilot Study of Intralesional Injection of Triamcinolone Acetonide for Desmoid Tumors Recruiting NCT03627741 Phase 1 Triamcinolone Acetonide
33 Comparison of the Blister Fluid Components of Second Degree Burned Patients With the Blister Fluid Components Following Intralesional Cryosurgery of Keloid Scars - A Feasibility Study. Unknown status NCT01627769
34 Dermatix; A Randomized Controlled Trial Measuring Effectivity of Dermatix in Promoting Scar Maturation of Hypertrophic Scars. Unknown status NCT00548210
35 Tunable-Dye Laser Therapy to Ameliorate Hypertrophic Scarring in Burned Children Unknown status NCT01653691
36 Comparison of the Effectiveness in Prevention of Hypertrophic Scars or Keloids Between Silicone Sheet, Silicone Gel and Paper Steri-strip-A Randomised Controlled Trial. Unknown status NCT00849004
37 Intralesional Cryosurgery for the Treatment of Basal Cell Carcinoma of the Lower Extremities in the Elderly - a Feasibility Study Unknown status NCT01633515
38 Intralesional Cryotherapy With a Argon Gas Based Device for the Treatment of Keloid and Hypertrophic Scars Completed NCT02063243
39 Intralesional Cryotherapy for Treatment of Keloid Scars: a Prospective Evaluation Completed NCT01994616
40 Randomized, Controlled, Within-patient, Single-blinded Pilot Study to Evaluate the Efficacy of the Ablative Fractional CO2 Laser in the Treatment of Hypertrophic Scars in Adult Burn Patients Completed NCT03240718
41 Effect of Pulse Width of a 595-nm Flashlamp-pumped Pulsed-dye Laser on the Treatment Response of Keloidal and Hypertrophic Sternotomy Scars Completed NCT00142441
42 Rejuvenation of Post Burn Scars on the Face With Unfiltered Nanofat Injection Completed NCT03352297
43 Pilot Study of Prospective Clinical Trials on Skin Wound Healing in Young and Aged Individuals Completed NCT01040104
44 Comparison of the Effectiveness of the Pulsed Dye Laser 585nm Versus 595nm in the Treatment of New Surgical Scars Completed NCT00482144
45 Effectiveness and Tolerability of an Overnight 4-week Treatment With Patch Containing Onion Extract and Allantoin for Cesarean Section Scars Completed NCT04046783
46 Observational Study of Keloids Scars Treated by Shaving and Cryosurgery Recruiting NCT02886091
47 Early Carbon Dioxide Laser Therapy for Alleviation of Incisional Scar Burden Recruiting NCT03306628
48 Understanding and Reversing Chronic Radiation Dermatitis - A Pilot Study Recruiting NCT01910818
49 Effects of Virtual Reality Based Rehabilitation on Burned Hands a Prospective, Randomized, Single Blined Study Recruiting NCT03865641
50 A Single-arm, Observational Study to Explore and Characterize Wound Healing After Skin Punch Biopsies in Healthy Volunteers Active, not recruiting NCT03433820

Search NIH Clinical Center for Hypertrophic Scars

Genetic Tests for Hypertrophic Scars

Anatomical Context for Hypertrophic Scars

MalaCards organs/tissues related to Hypertrophic Scars:

41
Skin, Breast, Endothelial, Bone, Liver, Smooth Muscle, Thyroid

Publications for Hypertrophic Scars

Articles related to Hypertrophic Scars:

(show top 50) (show all 1825)
# Title Authors PMID Year
1
Matrix metalloproteinases and tissue inhibitors of metalloproteinases in patients with different types of scars and keloids. 9 38
19464975 2010
2
Pentoxifylline modifies three-dimensional collagen lattice model contraction and expression of collagen types I and III by human fibroblasts derived from post-burn hypertrophic scars and from normal skin. 9 38
19303218 2009
3
Nonlinear spectral imaging of human hypertrophic scar based on two-photon excited fluorescence and second-harmonic generation. 9 38
19309369 2009
4
Tranilast, an anti-allergic drug, down-regulates the growth of cultured neurofibroma cells derived from neurofibromatosis type 1. 9 38
19282654 2009
5
[Expression of Notch receptors, ligands and downstream target genes in epidermis of hypertrophic scar]. 9 38
19408725 2009
6
Hic-5 promotes the hypertrophic scar myofibroblast phenotype by regulating the TGF-beta1 autocrine loop. 9 38
18401422 2008
7
Expression of Smad protein by normal skin fibroblasts and hypertrophic scar fibroblasts in response to transforming growth factor beta1. 9 38
18616749 2008
8
TGF-beta1 slows the growth of pathogenic myofibroblasts through a mechanism requiring the focal adhesion protein, Hic-5. 9 38
17671518 2008
9
[Expression of matrix metalloproteinase-2, -9 and their inhibitor-1 in hypertrophic scars]. 9 38
18457258 2007
10
Basic fibroblast growth factor reduces scar formation in acute incisional wounds. 9 38
17971006 2007
11
Differential p63 and p53 expression in human keloid fibroblasts and hypertrophic scar fibroblasts. 9 38
17688405 2007
12
Upregulation of TGF-beta1 expression may be necessary but is not sufficient for excessive scarring. 9 38
16498396 2006
13
Upregulation of the Wnt/beta-catenin pathway induced by transforming growth factor-beta in hypertrophic scars and keloids. 9 38
16874413 2006
14
[Effect of asiaticoside on the expression of transforming growth factor-beta mRNA and matrix metalloproteinases in hypertrophic scars]. 9 38
16495179 2006
15
A basic fibroblast growth factor improved the quality of skin grafting in burn patients. 9 38
16199295 2005
16
Hypertrophic scar fibroblasts have increased connective tissue growth factor expression after transforming growth factor-beta stimulation. 9 38
16217483 2005
17
[A study of the abnormalities of human epiderm in keloids and hypertrophic scars]. 9 38
15363271 2004
18
Gene expression profiles from hypertrophic scar fibroblasts before and after IL-6 stimulation. 9 38
15095275 2004
19
Fibrillin-1 and elastin are differentially expressed in hypertrophic scars and keloids. 9 38
15086768 2004
20
[Distribution and expression of transforming growth factor beta and their receptors in hypertrophic scar]. 9 38
15059449 2004
21
Genetic susceptibility to keloid disease and hypertrophic scarring: transforming growth factor beta1 common polymorphisms and plasma levels. 9 38
12560674 2003
22
Intervention with tranilast attenuates renal pathology and albuminuria in advanced experimental diabetic nephropathy. 9 38
14694265 2003
23
[Experimental study of the expression of c-myc, c-fos and proto-oncogenes on hypertrophic and scars]. 9 38
12189705 2002
24
Release and activation of matrix metalloproteinase-9 during in vitro mechanical compression in hypertrophic scars. 9 38
11939809 2002
25
Detection of collagens in hypertrophic scars by picrosirius polarization method. 9 38
12390767 2002
26
[Change of gene expression of transforming growth factor-beta1, Smad 2 and Smad 3 in hypertrophic scars skins]. 9 38
11955370 2002
27
[Expression of alpha-smooth muscle actin in scar fibroblasts in vitro]. 9 38
11762220 2001
28
Expression of oncoproteins c-fos and c-jun in hypertrophic scars and chronic dermal ulcers and their regulation of basic fibroblast growth factor. 9 38
11780366 2001
29
Altered expression of keratins during abnormal wound healing in human skin. 9 38
11219730 2001
30
[The significance and characteristics of the gene expressions of c-fos and c-jun in hypertrophic scar and chronic ulcer tissues]. 9 38
11876891 2000
31
[Characteristics of bFGF and TGF-beta expression in dermal chronic ulcers and hypertrophic scars and their effects on tissue repair]. 9 38
12516473 2000
32
[A study on the expressions and the correlation of TGF-beta and alpha-SMA in scars]. 9 38
11593622 2000
33
Delayed appearance of decorin in healing burn scars. 9 38
10692030 2000
34
Expression of Bcl-2, p53, c-jun and c-fos protooncogenes in keloids and hypertrophic scars. 9 38
10651227 1999
35
Exogenous transforming growth factor beta(2) modulates collagen I and collagen III synthesis in proliferative scar xenografts in nude rats. 9 38
10600349 1999
36
Gelatinase activity in keloids and hypertrophic scars. 9 38
10417752 1999
37
Cytokine expression is downregulated by collagen-polyvinylpyrrolidone in hypertrophic scars. 9 38
9804346 1998
38
Transforming growth factor-beta in thermally injured patients with hypertrophic scars: effects of interferon alpha-2b. 9 38
9773986 1998
39
Hypertrophic scarring is associated with epidermal abnormalities: an immunohistochemical study. 9 38
9924436 1998
40
Activated keratinocytes in the epidermis of hypertrophic scars. 9 38
9588880 1998
41
Enhanced expression of transforming growth factor-beta type I and type II receptors in wound granulation tissue and hypertrophic scar. 9 38
9466575 1998
42
Primary ex vivo culture of keratinocytes isolated from hypertrophic scars as a means of biochemical characterization of CD36. 9 38
9594363 1998
43
Cytokine mRNA changes during the treatment of hypertrophic scars with silicone and nonsilicone gel dressings. 9 38
9063511 1996
44
[Comparative study of collagen in hypertrophic and keloid cicatrix]. 9 38
9139458 1996
45
Chemical characterization and quantification of proteoglycans in human post-burn hypertrophic and mature scars. 9 38
8665780 1996
46
Acceleration of wound healing in diabetic mice by basic fibroblast growth factor. 9 38
8860952 1996
47
Differential expression of IGFBPs by normal and hypertrophic scar fibroblasts. 9 38
8592408 1996
48
Immunohistochemical localization of the proteoglycans decorin, biglycan and versican and transforming growth factor-beta in human post-burn hypertrophic and mature scars. 9 38
7544762 1995
49
Modulation of collagen synthesis by transforming growth factor-beta in keloid and hypertrophic scar fibroblasts. 9 38
7979045 1994
50
Fibronectin gene expression differs in normal and abnormal human wound healing. 9 38
17168907 1994

Variations for Hypertrophic Scars

Expression for Hypertrophic Scars

Search GEO for disease gene expression data for Hypertrophic Scars.

Pathways for Hypertrophic Scars

Pathways related to Hypertrophic Scars according to GeneCards Suite gene sharing:

(show top 50) (show all 63)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.56 TIMP1 TGFB3 TGFB1 SMAD3 SMAD2 MMP2
2
Show member pathways
13.39 TIMP1 TGFB3 TGFB1 SMAD3 SMAD2 BMP6
3
Show member pathways
13.36 TGFB1 SMAD3 SMAD2 MMP2 KRT16 CD36
4
Show member pathways
13.16 TIMP1 TGFB3 TGFB1 SMAD3 BMP6
5
Show member pathways
12.96 TGFB3 TGFB1 SMAD3 SMAD2
6
Show member pathways
12.93 TGFB1 SMAD3 SMAD2 MMP2 KRT16
7
Show member pathways
12.92 TIMP1 TGFB3 TGFB1 BMP6
8
Show member pathways
12.91 TIMP1 TGFB3 TGFB1 BMP6
9
Show member pathways
12.75 TGFB3 TGFB1 SMAD3 SMAD2
10 12.71 TGFB3 TGFB1 SMAD3 SMAD2 MMP2
11
Show member pathways
12.66 TGFB3 TGFB1 SMAD3 SMAD2
12
Show member pathways
12.64 TIMP1 TGFB3 TGFB1 MMP2
13
Show member pathways
12.6 TIMP1 TGFB3 TGFB1 BMP6
14
Show member pathways
12.51 TGFB3 TGFB1 SMAD3 SMAD2
15
Show member pathways
12.38 TGFB3 TGFB1 SMAD3 SMAD2
16
Show member pathways
12.29 TIMP1 TGFB3 TGFB1 BMP6
17 12.27 TGFB3 TGFB1 SMAD3 SMAD2
18 12.26 TGFB3 TGFB1 SMAD3 SMAD2
19 12.2 TGFB1 SMAD2 MMP2
20
Show member pathways
12.19 TGFB1 SMAD3 SMAD2
21
Show member pathways
12.18 TIMP1 TGFB3 TGFB1 BMP6
22 12.15 TGFB3 TGFB1 SMAD3 SMAD2 BMP6
23
Show member pathways
12.13 TGFB1 SMAD3 SMAD2
24 12.09 TGFB3 TGFB1 SMAD3 SMAD2
25 12.07 TGFB3 TGFB1 SMAD3 SMAD2 MMP2
26
Show member pathways
12.04 TGFB1 SMAD3 MMP2
27 12.02 TGFB3 TGFB1 SMAD3 SMAD2 BMP6
28
Show member pathways
12.01 TGFB3 TGFB1 SMAD3 SMAD2
29 11.99 TGFB1 SMAD3 SMAD2
30
Show member pathways
11.97 TGFB3 TGFB1 SMAD3 SMAD2
31 11.91 TIMP1 TGFB1 MMP2 CD36
32
Show member pathways
11.89 TIMP1 TGFB3 TGFB1 SMAD3 SMAD2 BMP6
33
Show member pathways
11.82 TGFB1 SMAD3 SMAD2
34 11.81 TGFB3 TGFB1 SMAD3 SMAD2
35 11.76 TIMP1 TGFB3 TGFB1 MMP2
36
Show member pathways
11.72 TGFB1 SMAD3 SMAD2
37 11.68 TGFB1 SMAD3 SMAD2
38 11.67 TGFB3 TGFB1 CD36
39
Show member pathways
11.66 TGFB1 SMAD3 SMAD2
40 11.65 TIMP1 TGFB3 TGFB1 BMP6
41 11.65 TGFB3 TGFB1 SMAD3 SMAD2 MMP2
42 11.62 SMAD3 SMAD2 MMP2
43 11.6 TIMP1 TGFB1 MMP2
44 11.55 TGFB1 SMAD3 SMAD2
45 11.53 TGFB3 TGFB1 SMAD3 SMAD2 BMP6
46 11.49 TGFB3 TGFB1 SMAD3 SMAD2
47 11.46 TGFB3 TGFB1 CD36
48
Show member pathways
11.46 TGFB3 TGFB1 SMAD3 SMAD2 MMP2
49 11.41 TGFB3 TGFB1
50 11.39 SMAD3 SMAD2

GO Terms for Hypertrophic Scars

Cellular components related to Hypertrophic Scars according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.73 TIMP1 TGFB3 TGFB1 MMP2 CD36 BMP6
2 collagen-containing extracellular matrix GO:0062023 9.5 TGFB3 TGFB1 MMP2
3 SMAD protein complex GO:0071141 9.16 SMAD3 SMAD2
4 platelet alpha granule lumen GO:0031093 9.13 TIMP1 TGFB3 TGFB1
5 heteromeric SMAD protein complex GO:0071144 8.62 SMAD3 SMAD2

Biological processes related to Hypertrophic Scars according to GeneCards Suite gene sharing:

(show top 50) (show all 72)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of cell proliferation GO:0008285 9.99 TGFB3 TGFB1 SMAD3 SMAD2
2 positive regulation of gene expression GO:0010628 9.99 TGFB1 SMAD3 SMAD2 CD36
3 cytokine-mediated signaling pathway GO:0019221 9.96 TIMP1 TGFB1 MMP2 CD36
4 regulation of apoptotic process GO:0042981 9.91 TGFB3 TGFB1 BMP6
5 negative regulation of gene expression GO:0010629 9.91 TGFB1 SMAD2 CD36
6 in utero embryonic development GO:0001701 9.89 TGFB3 SMAD3 SMAD2
7 aging GO:0007568 9.88 TIMP1 TGFB3 TGFB1 KRT16
8 response to hypoxia GO:0001666 9.88 TGFB3 TGFB1 SMAD3 MMP2
9 regulation of MAPK cascade GO:0043408 9.81 TGFB3 TGFB1 BMP6
10 cell development GO:0048468 9.8 TGFB3 TGFB1 BMP6
11 platelet degranulation GO:0002576 9.8 TIMP1 TGFB3 TGFB1 CD36
12 positive regulation of pathway-restricted SMAD protein phosphorylation GO:0010862 9.78 TGFB3 TGFB1 BMP6
13 ureteric bud development GO:0001657 9.77 TGFB1 SMAD3 SMAD2
14 positive regulation of protein secretion GO:0050714 9.77 TGFB3 TGFB1 BMP6
15 transforming growth factor beta receptor signaling pathway GO:0007179 9.76 TGFB3 TGFB1 SMAD3 SMAD2
16 T cell activation GO:0042110 9.75 TGFB1 SMAD3
17 negative regulation of fat cell differentiation GO:0045599 9.74 TGFB1 SMAD3
18 positive regulation of cell division GO:0051781 9.74 TGFB3 TGFB1
19 extrinsic apoptotic signaling pathway GO:0097191 9.74 TGFB1 SMAD3
20 positive regulation of nitric oxide biosynthetic process GO:0045429 9.74 SMAD3 CD36
21 response to progesterone GO:0032570 9.74 TGFB3 TGFB1
22 negative regulation of mitotic cell cycle GO:0045930 9.73 TGFB1 SMAD3
23 mammary gland development GO:0030879 9.73 TGFB3 TGFB1
24 gastrulation GO:0007369 9.73 SMAD3 SMAD2
25 embryonic cranial skeleton morphogenesis GO:0048701 9.73 SMAD3 SMAD2
26 digestive tract development GO:0048565 9.73 TGFB3 TGFB1
27 positive regulation of protein import into nucleus GO:0042307 9.73 TGFB1 SMAD3
28 negative regulation of transforming growth factor beta receptor signaling pathway GO:0030512 9.73 TGFB3 TGFB1 SMAD3 SMAD2
29 mesoderm formation GO:0001707 9.72 SMAD3 SMAD2
30 developmental growth GO:0048589 9.72 SMAD3 SMAD2
31 positive regulation of pri-miRNA transcription by RNA polymerase II GO:1902895 9.72 TGFB1 SMAD3
32 positive regulation of collagen biosynthetic process GO:0032967 9.71 TGFB3 TGFB1
33 adrenal gland development GO:0030325 9.71 SMAD3 SMAD2
34 positive regulation of chondrocyte differentiation GO:0032332 9.71 SMAD3 BMP6
35 embryonic pattern specification GO:0009880 9.71 SMAD3 SMAD2
36 face morphogenesis GO:0060325 9.71 TGFB3 TGFB1 MMP2
37 signal transduction involved in regulation of gene expression GO:0023019 9.7 SMAD3 SMAD2
38 activin receptor signaling pathway GO:0032924 9.7 SMAD3 SMAD2
39 secondary palate development GO:0062009 9.7 TGFB3 SMAD2
40 endoderm development GO:0007492 9.7 TGFB1 SMAD3 SMAD2
41 lens fiber cell differentiation GO:0070306 9.69 TGFB1 SMAD3
42 cell-cell junction organization GO:0045216 9.69 TGFB3 TGFB1 SMAD3
43 cell activation GO:0001775 9.68 TIMP1 TGFB1
44 salivary gland morphogenesis GO:0007435 9.68 TGFB3 TGFB1
45 response to cholesterol GO:0070723 9.68 TGFB1 SMAD2
46 primary miRNA processing GO:0031053 9.68 SMAD3 SMAD2
47 nodal signaling pathway GO:0038092 9.67 SMAD3 SMAD2
48 pericardium development GO:0060039 9.67 SMAD3 SMAD2
49 embryonic foregut morphogenesis GO:0048617 9.67 SMAD3 SMAD2
50 response to laminar fluid shear stress GO:0034616 9.66 TGFB3 TGFB1

Molecular functions related to Hypertrophic Scars according to GeneCards Suite gene sharing:

(show all 13)
# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.67 TIMP1 TGFB3 TGFB1 BMP6
2 protein heterodimerization activity GO:0046982 9.65 TGFB3 TGFB1 SMAD3 SMAD2 BMP6
3 R-SMAD binding GO:0070412 9.52 SMAD3 SMAD2
4 transforming growth factor beta binding GO:0050431 9.51 TGFB3 CD36
5 enhancer binding GO:0035326 9.49 SMAD3 SMAD2
6 co-SMAD binding GO:0070410 9.48 SMAD3 SMAD2
7 primary miRNA binding GO:0070878 9.46 SMAD3 SMAD2
8 growth factor activity GO:0008083 9.46 TIMP1 TGFB3 TGFB1 BMP6
9 type II transforming growth factor beta receptor binding GO:0005114 9.43 TGFB3 TGFB1
10 transforming growth factor beta receptor, pathway-specific cytoplasmic mediator activity GO:0030618 9.4 SMAD3 SMAD2
11 type III transforming growth factor beta receptor binding GO:0034714 9.32 TGFB3 TGFB1
12 type I transforming growth factor beta receptor binding GO:0034713 9.13 TGFB3 TGFB1 SMAD2
13 transforming growth factor beta receptor binding GO:0005160 9.02 TGFB3 TGFB1 SMAD3 SMAD2 BMP6

Sources for Hypertrophic Scars

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....